Key Laboratory of Molecular Target & Clinical Pharmacology and the State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, 511436, PR China.
Guangdong Provincial Key Laboratory of Construction and Detection in Tissue Engineering, Biomaterials Research Center, School of Biomedical Engineering, Southern Medical University, Guangzhou, 510515, PR China.
Biomaterials. 2021 Jun;273:120854. doi: 10.1016/j.biomaterials.2021.120854. Epub 2021 Apr 26.
The development of photodynamic therapy (PDT) is severely limited by short half-life of singlet oxygen (O) and the hypoxic microenvironment. In this work, a plasma membrane targeted photodynamic O economizer (designated as P-POE) is developed to improve the subcellular delivery of photosensitizers and alleviate the tumor hypoxia for enhanced PDT effect. After self-assembly into nanomicelles, P-POE has a relatively high stability and a favorable photochemical performance, which are conducive to boosting the O production. Besides, the plasma membrane anchoring of P-POE contributes to enhancing the preferential retention and cellular accumulation of photosensitizers on tumor tissues and cells. More importantly, P-POE-induced mitochondrial respiratory depression is demonstrated to reduce the O consumption of tumor cells to relieve the hypoxia. Consequently, P-POE still exhibits a robust PDT effect against hypoxic tumors, which greatly inhibits the proliferation of breast cancer with low adverse reactions. This innovative combination of subcellular targeting and hypoxic alleviation would advance the development of individualized drug delivery systems for photodynamic therapy against hypoxic tumors.
光动力疗法(PDT)的发展受到单线态氧(O)半衰期短和缺氧微环境的严重限制。在这项工作中,开发了一种细胞膜靶向光动力 O 节约剂(命名为 P-POE),以提高光敏剂的亚细胞递送并减轻肿瘤缺氧以增强 PDT 效果。自组装成纳米胶束后,P-POE 具有较高的稳定性和良好的光化学性能,有利于促进 O 的产生。此外,P-POE 的细胞膜锚定有助于增强光敏剂在肿瘤组织和细胞上的优先保留和细胞积累。更重要的是,已经证明 P-POE 诱导的线粒体呼吸抑制可减少肿瘤细胞对 O 的消耗,从而缓解缺氧。因此,P-POE 仍然对缺氧肿瘤表现出强大的 PDT 效果,极大地抑制了具有低不良反应的乳腺癌的增殖。这种亚细胞靶向和缺氧缓解的创新结合将推进针对缺氧肿瘤的个性化药物传递系统的光动力疗法的发展。